This comprehensive volume, with contributions from leading experts, provides a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. The volume addresses: understanding lung cancer- statistics and epidemiology of lung cancer, along with the incidence of lung cancer in non-smokers; state of current therapies-immune, targeted therapies against EGFR TKIs, KRAS, ALK and the associate challenges, especially resistance mechanisms; recent progress in targeted drug development based on metal chemistry and genomics; emerging biomarkers and therapeutic targets such as EMT, cancer stem cells, and the tumor microenvironment; current personalized clinical management and radiation therapy for lung cancers; and the promise of epigenetics and next-generation sequencing for the advancements towards personalized therapy for lung cancer patients.